FarmavitaR+

1. Introduction of Braille script for pharmaceuticals in Ukraine
(Regulatory Affairs/Europe not-EU)

... 7 years preparation for new law concerning the Braille script. What does it mean for producers of drugs? All new registration and renewal procedures from 01.01.10 would include part respondent ...

2. Emerging Clinical Trial Locations
(Clinical Trilas/Europe not-EU)

... at $250m in 2008. The market is expected to grow at a CAGR of 33% over the next four years to reach $791m in 2012. By that time, Chinese CROs will account for an estimated 2.3% of the global CRO market. ...

3. Standardization of Herbal Drugs
(Professional Articles/Life Science Article)

... an interdisciplinary approach wherein the pharmacognosist, chemist and the biologist work together. In recent years there has been a tremendous demand for herbal drugs especially in developed countries ...

4. Drug repositioning
(Regulatory Affairs/Other issues)

... of years now. The increasingly harsh global drug pricing environment coupled with rapid generic erosion in many of the largest and therefore most lucrative markets means that pharmaceutical companies are ...

5. Early Stage Drug Safety Strategies and Risk Management
(Reports/Market Report)

Maximizing opportunities towards achieving clinical success For the last few years the biggest pharma companies have started to bring new technologies for drug safety prediction into the discovery ...

6. Russia’s Emerging OTC Market Holds Problems As Well As Promise
(Regulatory Affairs/Europe not-EU)

... find the money,'" he added. Indeed, Russia's gross domestic product grew 6 percent in 2008 despite the current recession and grew an average of 7 percent annually in the previous 10 years, according ...

7. Optimizing Brand Lifecycle Management
(Reports/Market Report)

... of their strategies in response to internal and external events. Lifecycle management should not be left until only few years are left to patent expiry. Revenues can be maximized during launch ...

8. eCTD
(eSubmissions/eSubmissions)

... management requirements of the regulatory affairs department. Staying ahead Whatever their ambitions with regard to emerging markets, with the drug discovery-to-market lifecycle as long as 12 years, ...

9. Chinese Pharmaceutical Market Overview
(Reports/Market Report)

... has experienced pronounced and rapid expansion in recent years, driven by the growth of both Chinese and Western manufacturers. Increasingly, there is a shift towards a research-based industry, focused ...

10. Canadian Generics Market
(Reports/Market Report)

... market for generics manufacturers. Although historically dominated by domestic generics companies, mergers and acquisitions over the last five years have increased the dominance of foreign players.  ...

11. Market Trends
(Reports/Market Report)

... cost of developing novel products. With a decrease in R&D productivity in recent years, in order to maximize the return on investment, drugs launched in the US and 5EU markets between 2002 ...

12. The Indian Pharmaceutical Market
(Reports/Market Report)

... high market growth. The Indian Pharmaceutical Market to 2011 provides a detailed analysis of the leading players and discusses how they are planning to sustain growth over the next five years. For each ...

13. Drug Development Opportunities in China
(Reports/Market Report)

... time consuming, with new products typically requiring investment of over 4 years and $1billion from concept to commercialization. As a result, China has emerged as an increasingly attractive option ...

14. The Future of Targeted Therapeutics
(Reports/Company Report)

The Future of Targeted Therapeutics: Key technologies, new therapy area applications In recent years, the maximization of blockbuster revenues has been compromised by generic price erosion and ...

15. Development of International OTC Bradns
(Regulatory Affairs/Rx to OTC )

... as SB12, Zon, Lactal and Eeze have contributed strongly to Antula becoming the fastest growing OTC healthcare business in its local markets over recent years. HBI is funded by an international syndicate ...

16. Dendrimers - Drug Delivery to Cancer
(Professional Articles/Life Science Article)

... number of ‘controllable’ peripheral functionalities.  In recent years, there has been an increasing interest in the field of dendrimers. In particular, the intrinsic connectivity ...

17. Rhinitis - Market Research
(Reports/Market Report)

... men and women. 4. AGE OF ONSET  Common in childhood,adolescence and early adult years, which mean age of onset 8-11 years, but atopic rhinitis may occur in persons of any age. In 80% ...

18. Nanotubes Against Cancer
(Professional Articles/Life Science Article)

... and thermal conductivity. Over the past two years, researchers have demonstrated repeatedly that certain types of carbon nanotubes are among the most effective materials known for transporting proteins, ...

19. A Breakthrough on Stem Cells
(Professional Articles/Life Science Article)

... years of experience. That's why nearly every major stem cell lab began looking for an alternative approach, the most promising of which was to simply reprogram adult cells without eggs or embryos. ...

20. Antimalarial Drugs
(Professional Articles/Life Science Article)

... drug. The only important additions of the recent years are Mefloquine, Atovaquone and Artemisinin for resistant falciparum malaria. However, these drugs have adverse effect on our body system. Seeing ...